Hanmi Pharmaceutical
128940.KS · Bio
Korea's largest pharmaceutical company by revenue. Known for proprietary LAPSCOVERY long-acting platform technology, with multi-billion-dollar global licensing deals in obesity and diabetes therapeutics.
Latest news
K-Bio Targets Next-Generation Obesity Treatments at ADA 2026
Hanmi Pharmaceutical Seals First Big Deal in 6 Years With Lilly Licensing Pact
Hanmi Pharmaceutical Licenses GLP-2 Drug Candidate to Eli Lilly in $1.26 Billion Deal
Corporate Disclosures
Eli Lilly Bets 1.9 Trillion Won on Hanmi's GLP-2 Drug
Hanmi Pharm Surges 13% on $1.26 Billion Eli Lilly Licensing Deal
Hanmi Pharmaceutical Unveils First Research on Muscle-Boosting Obesity Drug
Korean Pharma Firms Race to Adopt AI Across Drug Development
Hanmi Pharmaceutical Partners with Organon to Export Combination Drugs to Southeast Asia
Korean Pharma Firms Race Toward Phase 3 Trial Results for Key Drugs
Hanmi Pharmaceutical Expands Obesity Drug Indication to Diabetes, Begins Phase 3 Dosing
Korea Dispatches Biohealth Delegation to Mexico, Brazil
Hanmi Pharmaceutical Creates Innovation Growth Division to Drive Obesity Drug Sales
Hanmi Pharmaceutical Creates Innovation Growth Division to Drive Obesity Drug Sales
Beijing Hanmi Surpasses 400 Billion Won in Annual Revenue for First Time
Korean Drugmakers Eye H2 Pipeline Catalysts After Q1 Earnings
Hanmi Science Q1 Operating Profit Jumps 24% to 33.6 Billion Won
Hanmi Pharmaceutical Q1 Operating Profit Falls 9.1% on Base Effect
Hanmi Pharmaceutical's Rolontis Wins IR52 Jang Young-shil Award
Samsung Bioepis Reaffirms Efficacy of Osteoporosis Treatment Obodence
Hanmi's Rolvedon Eyes Sales Rebound After US Partner's M&A
Hanmi Pharmaceutical Launches Commercialization Task Force for Obesity Drug Efpeglenatide
